PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
15784625-8	2005	Nectin-4 shedding is constitutive, strongly enhanced by 12-O-tetradecanoylphorbol-13-acetate activation, and reduced tumor necrosis factor-alpha protease inhibitor TAPI-1 or by the tissue inhibitor of metalloproteinase-3 (TIMP-3).	Tetradecanoylphorbol Acetate	56-92	nectin cell adhesion molecule 4	Homo sapiens	0-8
34108177-0	2021	Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin.	vedotin	118-125	nectin cell adhesion molecule 4	Homo sapiens	17-24
34725211-4	2021	To this end, we have developed BT7480, a novel, first-in-class, Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist  (Bicycle TICA ).	bt7480	31-37	nectin cell adhesion molecule 4	Homo sapiens	64-72
34725211-6	2021	Chemical conjugation of two CD137 Bicycles to a Nectin-4 Bicycle led to BT7480, which was then evaluated using a suite of in vitro and in vivo assays to characterize its pharmacology and mechanism of action.	bt7480	72-78	nectin cell adhesion molecule 4	Homo sapiens	48-56
34725211-8	2021	BT7480 binds potently, specifically, and simultaneously to Nectin-4 and CD137.	bt7480	0-6	nectin cell adhesion molecule 4	Homo sapiens	59-67
34687441-12	2022	Interestingly, the strong expression of Nectin-4 was correlated with high DCR.	dimethylamide-crotonin	74-77	nectin cell adhesion molecule 4	Homo sapiens	40-48
33943047-10	2021	Enfortumab vedotin, a monoclonal antibody targeting nectin-4 conjugated to monomethyl auristatin E, has demonstrated clinically significant efficacy in patients who do not respond to both cytotoxic chemotherapy and CPIs.	vedotin	11-18	nectin cell adhesion molecule 4	Homo sapiens	52-60
33943047-10	2021	Enfortumab vedotin, a monoclonal antibody targeting nectin-4 conjugated to monomethyl auristatin E, has demonstrated clinically significant efficacy in patients who do not respond to both cytotoxic chemotherapy and CPIs.	monomethyl auristatin E	75-98	nectin cell adhesion molecule 4	Homo sapiens	52-60
34302971-0	2021	Increased Nectin-4 Levels in Chronic Ketamine Abusers and the Relationship with Lower Urinary Tract Symptoms.	Ketamine	37-45	nectin cell adhesion molecule 4	Homo sapiens	10-18
34302971-2	2021	We examined the association of lower urinary tract symptoms and levels of Nectin-4, a member of the cell adhesion molecules that is essential for maintaining the urothelium barrier in chronic ketamine abusers.	Ketamine	192-200	nectin cell adhesion molecule 4	Homo sapiens	74-82
34302971-3	2021	We measured the plasma levels of Nectin-4 in 88 patients with ketamine dependence and 69 controls.	Ketamine	62-70	nectin cell adhesion molecule 4	Homo sapiens	33-41
34302971-5	2021	We found Nectin-4 levels were increased in ketamine-dependent patients compared to the controls (p <  0.0001).	Ketamine	43-51	nectin cell adhesion molecule 4	Homo sapiens	9-17
34302971-7	2021	Our results suggest an up-regulation of Nectin-4 following chronic and heavy ketamine use.	Ketamine	77-85	nectin cell adhesion molecule 4	Homo sapiens	40-48
34302971-8	2021	Patients with ketamine dependence with a compromised upregulation of Nectin-4 are likely to have more severe urinary tract symptoms.	Ketamine	14-22	nectin cell adhesion molecule 4	Homo sapiens	69-77
34302971-9	2021	The mechanisms underlying the involvement of Nectin-4 in ketamine addiction and bladder toxicity warrant future investigation.	Ketamine	57-65	nectin cell adhesion molecule 4	Homo sapiens	45-53
34281911-1	2021	Nectin-4 is the target for enfortumab vedotin, a novel antibody-drug conjugate.	vedotin	38-45	nectin cell adhesion molecule 4	Homo sapiens	0-8
34281911-2	2021	NECTIN4 gene expression differs considerably across different molecular subtypes and has shown to be crucial in enfortumab vedotin efficacy.	vedotin	123-130	nectin cell adhesion molecule 4	Homo sapiens	0-7
34108177-8	2021	Results: NECTIN4 expression is heterogenous across molecular subtypes of bladder cancer and significantly enriched in luminal subtypes.	Phenobarbital	118-125	nectin cell adhesion molecule 4	Homo sapiens	9-16
34108177-9	2021	NECTIN4 expression is positively correlated with luminal markers GATA3, FOXA1, and PPARG across all cohorts.	Phenobarbital	49-56	nectin cell adhesion molecule 4	Homo sapiens	0-7
34108177-10	2021	NECTIN4 expression is both necessary and sufficient for EV sensitivity in luminal and basal subtypes of urothelial bladder cancer cells.	Phenobarbital	74-81	nectin cell adhesion molecule 4	Homo sapiens	0-7
34108177-12	2021	Conclusions: Sensitivity to EV is mediated by expression of NECTIN4, which is enriched in luminal subtypes of bladder cancer.	Phenobarbital	90-97	nectin cell adhesion molecule 4	Homo sapiens	60-67
34578231-10	2021	This in silico and in vitro approach suggests the possibility that CDV interacts with ortholog human SLAM (hSLAM) and human Nectin-4 receptors to infect human cell lines, which could imply a potential cross-species transmission of CDV from dogs to humans.	Cidofovir	67-70	nectin cell adhesion molecule 4	Homo sapiens	124-132
34578231-10	2021	This in silico and in vitro approach suggests the possibility that CDV interacts with ortholog human SLAM (hSLAM) and human Nectin-4 receptors to infect human cell lines, which could imply a potential cross-species transmission of CDV from dogs to humans.	Cidofovir	231-234	nectin cell adhesion molecule 4	Homo sapiens	124-132
35421529-4	2022	Namely, the increasing knowledge of the pathogenesis and molecular pathways underlying cancer development and progression is leading the introduction of target therapies such as the recently approved fibroblastic growth factor receptor (FGFR) inhibitor erdafitinib or the anti-nectin 4 antibody drug-conjugated enfortumab vedotin.	vedotin	322-329	nectin cell adhesion molecule 4	Homo sapiens	277-285
35466857-3	2022	Enfortumab vedotin-ejfv is a first-in-class monoclonal antibody drug conjugate that binds Nectin-4, a protein expressed on bladder cancer cells, and delivers the tubulin toxin, monomethyl auristatin E, into the cell causing cell death.	vedotin-ejfv	11-23	nectin cell adhesion molecule 4	Homo sapiens	90-98
32945172-0	2021	Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.	-ejfv	18-23	nectin cell adhesion molecule 4	Homo sapiens	47-55
35484425-3	2022	Recently, enfortumab vedotin, targeting cancer-associated NECTIN4, has been approved for the treatment of advanced urothelial carcinoma.	vedotin	21-28	nectin cell adhesion molecule 4	Homo sapiens	58-65
35312963-4	2022	Enfortumab vedotin, an ADC against Nectin-4, has demonstrated efficacy against solid tumor malignancies.	vedotin	11-18	nectin cell adhesion molecule 4	Homo sapiens	35-43
35269424-3	2022	The increasing knowledge of the pathogenesis and molecular pathways underlying cancer development and progression is leading the introduction of target therapies, such as the recently approved FGFR inhibitor Erdafitinib, or the anti-nectin 4 antibody drug-conjugate Enfortumab vedotin.	vedotin	277-284	nectin cell adhesion molecule 4	Homo sapiens	233-241
33945869-4	2021	Nectin-4 expression positively correlated with occurrence risk factors associated with breast cancer (alcohol, smoke, lifestyle habit, etc), CXCR4 expression, and LYVE-1-lymphatic vessel density (LVD).	Alcohols	102-109	nectin cell adhesion molecule 4	Homo sapiens	0-8
33991512-2	2021	Enfortumab vedotin is an antibody-drug conjugate directed at Nectin-4, a protein highly expressed in urothelial carcinoma.	vedotin	11-18	nectin cell adhesion molecule 4	Homo sapiens	61-69
33945869-7	2021	Nectin-4 stimulated the expressions of CXCR4 and CXCL12 under hypoxic conditions in ALN derived primary cells.	aln	84-87	nectin cell adhesion molecule 4	Homo sapiens	0-8
33692500-0	2021	Benefit of nectin-4 targeting with enfortumab vedotin confirmed.	vedotin	46-53	nectin cell adhesion molecule 4	Homo sapiens	11-19
33901032-1	2021	The antibody-drug conjugate enfortumab-vedotin acts by targeting nectin-4, a protein that is nearly ubiquitously expressed in conventional urothelial cancer.	vedotin	39-46	nectin cell adhesion molecule 4	Homo sapiens	65-73
33373686-13	2021	Thus, Curcumin-Veliparib combination suppresses angiogenesis through deregulation of the PI3K-AKT-eNOS pathway downstream to the NECTIN-4.	curcumin-veliparib	6-24	nectin cell adhesion molecule 4	Homo sapiens	129-137
33373686-0	2021	PARP inhibitor Veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: Role of nitric oxide (NO).	veliparib	15-24	nectin cell adhesion molecule 4	Homo sapiens	113-121
33373686-0	2021	PARP inhibitor Veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: Role of nitric oxide (NO).	veliparib	26-33	nectin cell adhesion molecule 4	Homo sapiens	113-121
33373686-0	2021	PARP inhibitor Veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: Role of nitric oxide (NO).	Curcumin	80-88	nectin cell adhesion molecule 4	Homo sapiens	113-121
33373686-6	2021	We observed that the soluble NECTIN-4 secreted from H357 oral cancer cells enhanced the angiogenesis of endothelial cells (HUVECs) and this was inhibited by Curcumin-Veliparib combination.	Curcumin	157-165	nectin cell adhesion molecule 4	Homo sapiens	29-37
33373686-6	2021	We observed that the soluble NECTIN-4 secreted from H357 oral cancer cells enhanced the angiogenesis of endothelial cells (HUVECs) and this was inhibited by Curcumin-Veliparib combination.	veliparib	166-175	nectin cell adhesion molecule 4	Homo sapiens	29-37
33373686-8	2021	Data indicated that NECTIN-4 mediated angiogenesis is associated with PI3K-AKT-mediated nitric oxide (NO) formation.	Nitric Oxide	88-100	nectin cell adhesion molecule 4	Homo sapiens	20-28
33373686-11	2021	Curcumin antagonised the NECTIN-4-induced angiogenesis through inhibition of PI3K-AKT mediated eNOS pathway and Veliparib synergized the effect of Curcumin.	Curcumin	0-8	nectin cell adhesion molecule 4	Homo sapiens	25-33
33373686-11	2021	Curcumin antagonised the NECTIN-4-induced angiogenesis through inhibition of PI3K-AKT mediated eNOS pathway and Veliparib synergized the effect of Curcumin.	veliparib	112-121	nectin cell adhesion molecule 4	Homo sapiens	25-33
32751328-1	2020	Enfortumab vedotin is a novel antibody-drug conjugate targeting Nectin-4, which is highly expressed in urothelial carcinoma.	vedotin	11-18	nectin cell adhesion molecule 4	Homo sapiens	64-72
33747934-1	2021	Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade.	vedotin	11-18	nectin cell adhesion molecule 4	Homo sapiens	24-32
33747934-1	2021	Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade.	Platinum	137-145	nectin cell adhesion molecule 4	Homo sapiens	24-32
33239713-5	2021	In the antibody-drug conjugate enfortumab vedotin, human anti-nectin-4 antibody is linked to the cytotoxic microtubule-disrupting agent monomethyl auristatin E.	vedotin	42-49	nectin cell adhesion molecule 4	Homo sapiens	62-70
33239713-5	2021	In the antibody-drug conjugate enfortumab vedotin, human anti-nectin-4 antibody is linked to the cytotoxic microtubule-disrupting agent monomethyl auristatin E.	monomethyl auristatin E	136-159	nectin cell adhesion molecule 4	Homo sapiens	62-70
33478111-9	2021	Monomethyl auristatin E, a cytotoxic part of NECTIN4-targeted antibody-drug conjugate, was effective for BRAF-mutated or BRAFi-resistant melanoma cells.	monomethyl auristatin E	0-23	nectin cell adhesion molecule 4	Homo sapiens	45-52
33019653-6	2020	The antibody-drug conjugates (ADCs) enfortumab vedotin (EV) and sacituzumab govitecan (SG) have demonstrated the ability to provide objective response rates (ORRs) of 44% and 31% in patients with bladder tumor cells that express Nectin-4 and Trop-2, respectively.	vedotin	47-54	nectin cell adhesion molecule 4	Homo sapiens	229-237
32603697-0	2020	Nanoformulated quinacrine regulates NECTIN-4 domain specific functions in cervical cancer stem cells.	Quinacrine	15-25	nectin cell adhesion molecule 4	Homo sapiens	36-44
32603697-5	2020	were used to delineate the function of each domain of NECTIN-4 in cancer and their regulation by nano-formulated quinacrine (NQC).	Quinacrine	113-123	nectin cell adhesion molecule 4	Homo sapiens	54-62
32824340-4	2020	Urothelial cancer is one such cancer, and clinical trials of enfortumab vedotin, a drug-conjugated anti-NECTIN4 antibody, are ongoing.	vedotin	72-79	nectin cell adhesion molecule 4	Homo sapiens	104-111
32555608-6	2020	The NECTIN4 gene within the adherens junction interaction pathway was associated with methadone dose in pathway-based genome wide association analyses (P = 0.0008).	Methadone	86-95	nectin cell adhesion molecule 4	Homo sapiens	4-11
32552213-1	2020	Introduction: In December 2019, the US Food and Drug Administration granted accelerated approval to the novel nectin-4-targeting antibody-drug conjugate, enfortumab vedotin, for the treatment of platinum-refractory and immune checkpoint blockade-refractory locally advanced or metastatic urothelial carcinoma.	vedotin	165-172	nectin cell adhesion molecule 4	Homo sapiens	110-118
32552213-1	2020	Introduction: In December 2019, the US Food and Drug Administration granted accelerated approval to the novel nectin-4-targeting antibody-drug conjugate, enfortumab vedotin, for the treatment of platinum-refractory and immune checkpoint blockade-refractory locally advanced or metastatic urothelial carcinoma.	Platinum	195-203	nectin cell adhesion molecule 4	Homo sapiens	110-118
32668516-6	2020	Enfortumab vedotin, a monoclonal antibody targeting nectin-4 conjugated to monomethyl auristatin E, has been approved for patients who do not respond to both cytotoxic chemotherapy and ICIs.	vedotin	11-18	nectin cell adhesion molecule 4	Homo sapiens	52-60
32668516-6	2020	Enfortumab vedotin, a monoclonal antibody targeting nectin-4 conjugated to monomethyl auristatin E, has been approved for patients who do not respond to both cytotoxic chemotherapy and ICIs.	monomethyl auristatin E	75-98	nectin cell adhesion molecule 4	Homo sapiens	52-60
32555608-10	2020	The results suggest involvement of genetic variants on NECTIN4 in methadone dose.	Methadone	66-75	nectin cell adhesion molecule 4	Homo sapiens	55-62
32413678-2	2020	Recent studies of measles virus haemagglutinin (MeV-H) and its receptor, including crystallographic and electron microscopic structural analyses combined with functional assays, have revealed how the MeV-H protein recognizes its cognate receptors, SLAM and Nectin-4, and how the glycan shield ensures effective vaccination.	Polysaccharides	279-285	nectin cell adhesion molecule 4	Homo sapiens	257-265
32542157-3	2020	Enfortumab vedotin targets nectin-4, a member of a family of calcium-dependent, immunoglobulin-like adhesion molecules found in adherens junctions and expressed in various epithelial malignancies, including bladder, breast, lung, ovarian, head/neck, and esophageal cancers.	Calcium	61-68	nectin cell adhesion molecule 4	Homo sapiens	27-35
32406880-1	2020	The antibody-drug conjugate enfortumab vedotin is a fully humanized monoclonal antibody targeting Nectin-4 linked to a microtubule-disrupting agent, monomethyl auristatin E, via a protease-cleavable maleimidocaproyl valine-citrulline linker.	vedotin	39-46	nectin cell adhesion molecule 4	Homo sapiens	98-106
32406880-1	2020	The antibody-drug conjugate enfortumab vedotin is a fully humanized monoclonal antibody targeting Nectin-4 linked to a microtubule-disrupting agent, monomethyl auristatin E, via a protease-cleavable maleimidocaproyl valine-citrulline linker.	maleimidocaproyl	199-215	nectin cell adhesion molecule 4	Homo sapiens	98-106
32406880-1	2020	The antibody-drug conjugate enfortumab vedotin is a fully humanized monoclonal antibody targeting Nectin-4 linked to a microtubule-disrupting agent, monomethyl auristatin E, via a protease-cleavable maleimidocaproyl valine-citrulline linker.	Valine	216-222	nectin cell adhesion molecule 4	Homo sapiens	98-106
32406880-1	2020	The antibody-drug conjugate enfortumab vedotin is a fully humanized monoclonal antibody targeting Nectin-4 linked to a microtubule-disrupting agent, monomethyl auristatin E, via a protease-cleavable maleimidocaproyl valine-citrulline linker.	Citrulline	223-233	nectin cell adhesion molecule 4	Homo sapiens	98-106
33604101-2	2020	Enfortumab vedotin, a Nectin-4-targeted antibody-drug conjugate, was recently approved by the U.S. Food & Drug Administration for patients with advanced or metastatic UC following chemotherapy and immunotherapy.	vedotin	11-18	nectin cell adhesion molecule 4	Homo sapiens	22-30
31823332-8	2020	Enfortumab vedotin, a nectin-4-targeted antibody conjugated with monomethyl auristatin E, is the first-in-class therapeutic option and has demonstrated unprecedented response rates following progression on chemotherapy and immunotherapy for advanced disease with a tolerable safety profile.	vedotin	11-18	nectin cell adhesion molecule 4	Homo sapiens	22-30
32031899-0	2020	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.	ev-101	0-6	nectin cell adhesion molecule 4	Homo sapiens	76-84
32031899-0	2020	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.	vedotin	51-58	nectin cell adhesion molecule 4	Homo sapiens	76-84
32031899-2	2020	METHODS: EV-101 is a phase I dose escalation/expansion study that enrolled patients with Nectin-4-expressing solid tumors (eg, metastatic urothelial carcinoma [mUC]) who progressed on >= 1 prior chemotherapy regimen and/or programmed death-1 receptor/programmed death ligand-1 [PD-(L)1] inhibitor, including a cohort of patients with mUC who received prior anti-PD-(L)1 therapy.	ev-101	9-15	nectin cell adhesion molecule 4	Homo sapiens	89-97
28232483-5	2017	We quantified Nectin-4 shedding from the surface of ovarian cancer cells after stimulation with lysophosphatidic acid.	lysophosphatidic acid	96-117	nectin cell adhesion molecule 4	Homo sapiens	14-22
31356140-2	2019	Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4, which is highly expressed in urothelial carcinoma.	enfortumab vedotin	0-18	nectin cell adhesion molecule 4	Homo sapiens	62-70
31526130-0	2019	Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.	enfortumab vedotin	0-18	nectin cell adhesion molecule 4	Homo sapiens	62-70
31526130-0	2019	Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.	monomethyl auristatin E	85-108	nectin cell adhesion molecule 4	Homo sapiens	62-70
31526130-4	2019	Enfortumab Vedotin (EV), a monoclonal antibody-drug conjugate (ADC) targeting nectin-4 is under investigation in patients with advanced UC.	enfortumab vedotin	0-18	nectin cell adhesion molecule 4	Homo sapiens	78-86
31526130-4	2019	Enfortumab Vedotin (EV), a monoclonal antibody-drug conjugate (ADC) targeting nectin-4 is under investigation in patients with advanced UC.	.alpha.-Glutamylvaline	20-22	nectin cell adhesion molecule 4	Homo sapiens	78-86
30603978-0	2019	Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation.	nanoquinacrine	0-14	nectin cell adhesion molecule 4	Homo sapiens	92-100
30603978-0	2019	Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation.	Fluorouracil	26-30	nectin cell adhesion molecule 4	Homo sapiens	92-100
30603978-5	2019	This study was designed to assess the role of Nectin-4 in the acquisition of 5-FU resistance by metastatic CC cells, including its relation to the NOTCH signalling pathway.	Fluorouracil	77-81	nectin cell adhesion molecule 4	Homo sapiens	46-54
30603978-8	2019	The role of Nectin-4 in the sensitization of 5-FU resistant metastatic CC cells upon incubation with Nano-formulated Quinacrine (NQC) was investigated using multiple bioassays including MTT, FACS, ELISA, immunoflurescence, Western blotting, comet and in vivo plasmid-based short patch and long patch base excision repair assays.	Quinacrine	117-127	nectin cell adhesion molecule 4	Homo sapiens	12-20
30603978-12	2019	After combination treatment of Nectin-4 overexpressing metastatic CC cells with a specific ADAM-17 inhibitor (GW280264) and NQC, a decreased Nectin-4 expression, without alterations in BER and/or other NOTCH pathway components, was noted.	gw280264	110-118	nectin cell adhesion molecule 4	Homo sapiens	31-39
30603978-12	2019	After combination treatment of Nectin-4 overexpressing metastatic CC cells with a specific ADAM-17 inhibitor (GW280264) and NQC, a decreased Nectin-4 expression, without alterations in BER and/or other NOTCH pathway components, was noted.	gw280264	110-118	nectin cell adhesion molecule 4	Homo sapiens	141-149
30865407-1	2019	Enfortumab vedotin is an antibody-drug conjugate targeting nectin-4 and is being studied in the treatment of various epithelial carcinomas including urothelial carcinoma; early data suggests efficacy and tolerability.	enfortumab vedotin	0-18	nectin cell adhesion molecule 4	Homo sapiens	59-67
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	AZD 6244	163-170	nectin cell adhesion molecule 4	Homo sapiens	102-109
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Lapatinib	172-181	nectin cell adhesion molecule 4	Homo sapiens	102-109
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Erlotinib Hydrochloride	183-192	nectin cell adhesion molecule 4	Homo sapiens	102-109
29066719-6	2017	We further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.	Paclitaxel	198-208	nectin cell adhesion molecule 4	Homo sapiens	102-109
26122960-5	2015	RESULTS: Increased NECTIN-4 expression was observed in 5-FU-resistant (5-FU-R) and 5-FU-exposed HCT-116 cells.	Fluorouracil	71-75	nectin cell adhesion molecule 4	Homo sapiens	19-27
26949052-8	2016	Inhibition of PI3K/AKT with LY294002 and/or Rac1 with NSC23766 impaired Nectin-4-mediated GBC cell proliferation and motility.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	28-36	nectin cell adhesion molecule 4	Homo sapiens	72-80
26122960-0	2015	NECTIN-4 increased the 5-FU resistance in colon cancer cells by inducing the PI3K-AKT cascade.	Fluorouracil	23-27	nectin cell adhesion molecule 4	Homo sapiens	0-8
26122960-5	2015	RESULTS: Increased NECTIN-4 expression was observed in 5-FU-resistant (5-FU-R) and 5-FU-exposed HCT-116 cells.	Fluorouracil	55-59	nectin cell adhesion molecule 4	Homo sapiens	19-27
26122960-7	2015	Apoptosis caused by 5-FU in 5-FU-R cells after NECTIN-4 knockdown indicates that NECTIN-4 is responsible for 5-FU resistance.	Fluorouracil	20-24	nectin cell adhesion molecule 4	Homo sapiens	81-89
26122960-5	2015	RESULTS: Increased NECTIN-4 expression was observed in 5-FU-resistant (5-FU-R) and 5-FU-exposed HCT-116 cells.	Fluorouracil	71-75	nectin cell adhesion molecule 4	Homo sapiens	19-27
26122960-7	2015	Apoptosis caused by 5-FU in 5-FU-R cells after NECTIN-4 knockdown indicates that NECTIN-4 is responsible for 5-FU resistance.	Fluorouracil	28-32	nectin cell adhesion molecule 4	Homo sapiens	81-89
26122960-9	2015	Drug combination of BCNU + Resveratrol decreased the cell survival and NECTIN-4 expressions in 5-FU-R cells and NECTIN-4-over-expressed cells.	Carmustine	20-24	nectin cell adhesion molecule 4	Homo sapiens	71-79
26122960-9	2015	Drug combination of BCNU + Resveratrol decreased the cell survival and NECTIN-4 expressions in 5-FU-R cells and NECTIN-4-over-expressed cells.	Carmustine	20-24	nectin cell adhesion molecule 4	Homo sapiens	112-120
26122960-9	2015	Drug combination of BCNU + Resveratrol decreased the cell survival and NECTIN-4 expressions in 5-FU-R cells and NECTIN-4-over-expressed cells.	Resveratrol	27-38	nectin cell adhesion molecule 4	Homo sapiens	71-79
26122960-9	2015	Drug combination of BCNU + Resveratrol decreased the cell survival and NECTIN-4 expressions in 5-FU-R cells and NECTIN-4-over-expressed cells.	Resveratrol	27-38	nectin cell adhesion molecule 4	Homo sapiens	112-120
26122960-10	2015	CONCLUSIONS: Our data suggest that NECTIN-4 is responsible for 5-FU resistance and BCNU + Resveratrol combination can be used to increase the 5-FU sensitivity.	Fluorouracil	63-67	nectin cell adhesion molecule 4	Homo sapiens	35-43
26122960-10	2015	CONCLUSIONS: Our data suggest that NECTIN-4 is responsible for 5-FU resistance and BCNU + Resveratrol combination can be used to increase the 5-FU sensitivity.	Fluorouracil	142-146	nectin cell adhesion molecule 4	Homo sapiens	35-43
26617807-3	2015	siRNA-nectin-4 plasma was constructed for the transfection into T cells using Lipofectamine 2000 reagent.	Lipofectamine	78-96	nectin cell adhesion molecule 4	Homo sapiens	6-14